Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 3/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.47 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.47 |
| ▸ | TXK | P42681 | 1/20 | 0.47 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.47 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | FLT1 | P17948 | 4/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618384 | 0.82 | KDR (0.59) | KDREGFR | |
| SCHEMBL29089850 | 0.80 | GAK (0.65) | GAKRIPK2ABL1EPHB6LCK | |
| SCHEMBL29200468 | 0.75 | GAK (0.61) | GAKRIPK2ABL1EPHB6LCK | |
| SCHEMBL5929206 | 0.75 | GAK (0.58) | GAKRIPK2ABL1EPHB6LCK | |
| SCHEMBL29200458 | 0.75 | GAK (0.64) | GAKRIPK2ABL1EPHB6LCK | |
| SCHEMBL4878852 | 0.72 | AURKA (0.71) | LCKSYK | |
| SCHEMBL317290 | 0.72 | MAPT (0.56) | BRD4 | |
| SCHEMBL23657809 | 0.72 | SYK (0.57) | KDRSYK | |
| SCHEMBL28845712 | 0.72 | EGFR (0.66) | GAKRIPK2ABL1EPHB6LCK | |
| SCHEMBL28845654 | 0.72 | GAK (0.58) | GAKRIPK2ABL1EPHB6LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007516273-A | — | — | 2007-06-21 | — | — | JP | claimed |
| CN-1890234-A | Novel quinoline derivatives | PFIZER (US) | 2007-01-03 | — | — | CN | claimed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | claimed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| CN-1890234-A | Novel quinoline derivatives | PFIZER (US) | 2007-01-03 | — | — | CN | disclosed |
| EP-1699780-A1 | NOVEL QUINOLINE DERIVATIVES | Pfizer, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063739-A1 | NOVEL QUINOLINE DERIVATIVES | PFIZER INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137395-A1 | Novel quinoline derivatives | AGOURON PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | COQ8B, COQ8A, MCM5 | GAK 2061/4885RIPK2 4029/4885ABL1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.